EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that it has signed an agreement that provides long-term, manufacturing capacity for NasulinTM, its intranasal insulin product candidate. Nasulin is currently in Phase II clinical trials for diabetes.
